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Abstract
Objectives—To examine HLA DRB1-DQB1 haplotypes within a multi-ethnic cohort and assess
their association with characteristics of diabetes onset.
Methods—The sample included 1,662 participants from the SEARCH for Diabetes in Youth
Study who tested positive for GADA and/or IA-2A autoantibodies. Blood drawn at the study visit
was used to measure fasting C-peptide and genotype HLA DRB1 and DQB1 loci. Diabetic
ketoacidosis (DKA) at diagnosis was determined from medical records. Multivariable linear and
logistic regression models stratified by race/ethnicity were used to assess associations with DRB1-
DQB1 haplotypes.
Results—The frequency of DRB1*03 susceptibility haplotypes ranged 27.5–28.9% in all racial/
ethnic groups. The frequency of susceptibility DRB1*04-DQB1*0302 was higher in non-Hispanic
white (NHW; 34.1%) and Hispanic (38.9%) compared to non-Hispanic black (NHB; 20.8%)
youth. Neutral and protective haplotypes were low frequency in all groups. DBR1*03 haplotypes
were associated with younger age at diagnosis in NHW and positivity for multiple autoantibodies
in Hispanics. DRB1*04-DQB1*0302 haplotypes were associated with multiple autoantibody
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positivity in NHW and Hispanics, and lower fasting C-peptide and higher odds of DKA in
Hispanics only. Although protective DRB1*04-DQB1*0301 haplotypes were associated with
older age at diagnosis in NHW, they were also associated with multiple autoantibody positivity in
these youth. Protective DRB1*13 haplotypes were associated with decreased odds of multiple
autoantibody positivity in NHB youth.
Conclusions—The distribution of DRB1-DQB1 haplotypes and their association with onset-
related characteristics of autoimmune diabetes varies across major racial/ethnic groups in the
United States. This may contribute to variation in clinical presentation of autoimmune diabetes by
race/ethnicity.
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INTRODUCTION
Type 1 diabetes mellitus is a chronic autoimmune disease characterized by progressive beta
cell destruction and subsequent insulin deficiency. Onset typically occurs in childhood or
adolescence, concomitant with the presence of autoantibodies such as glutamic acid
decarboxylase-65 (GADA) and insulinoma-associated antigen 2 (IA-2A) (1,2). First-degree
relatives of individuals with autoimmune diabetes are more likely to express these
autoantibodies and are at increased risk for developing type 1 diabetes, which indicates a
role for genetic factors in the etiology of the disease (3,4).
Key genetic determinants of the autoimmune component of type 1 diabetes have been
identified in the major histocompatibility class II regions of chromosome 6, such as Human
Leukocyte Antigen (HLA) DRB1 and DQB1 (5–11). Although susceptibility and resistance
to type 1 diabetes have mapped to these loci, studies reporting these associations were
conducted primarily in Caucasian populations (6,7,9,10). Few studies have investigated the
race/ethnicity-specific distribution of alleles at these HLA loci in black (5,12) or Hispanic
populations (11–13). Moreover, the joint effect of these loci on specific clinical
characteristics of onset and severity, especially in these minority populations, is not well
understood.
SEARCH for Diabetes in Youth (SEARCH) is a large multi-center observational study
among a racial/ethnically diverse population of children and adolescents with diabetes. We
describe the distribution of DRB1-DQB1 haplotypes in non-Hispanic white (NHW), non-
Hispanic black (NHB), and Hispanic youth with autoantibody-positive type 1 diabetes, and
examine the associations between these haplotypes and clinical characteristics of diabetes,
such as age at diagnosis, presence of diabetic ketoacidosis (DKA) at onset, multiple
autoantibody positivity, and fasting C-peptide (FCP) levels.
METHODS
Population and Data Sources
SEARCH began conducting population-based ascertainment of youth with clinically
diagnosed diabetes < 20 years of age in 2001 and continues to enroll youth with newly-
diagnosed (incident) diabetes (14). SEARCH participants who completed an initial survey
were asked to participate in an in-person study visit. At the time of the visit, informed
consent and assent (when applicable) were obtained, health questionnaires administered,
anthropometrics measured, and blood samples drawn from metabolically stable participants
(no episodes of DKA during the previous month) after a minimum 8-hour overnight fast. All
measures were conducted by trained, certified staff using standardized study protocols.
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Blood samples were processed locally and shipped within 24 hours to the central laboratory
(Northwest Lipid Metabolism and Diabetes Research Laboratories) for analysis. Institutional
review board(s) for each center approved the study protocol.
Demographic and Clinical Characteristics
Race/ethnicity was obtained through self-report using standard census questions (15). Youth
who reported Hispanic ethnicity were categorized as Hispanic; non-Hispanic youth who
reported more than one race (n=36) were categorized using the National Center for Health
Statistics’ plurality approach (16). According to this algorithm, youth who self-identified as
both black and NHW (n=26), or as black and Asian/Pacific Islander (n=1) were categorized
as NHB. Youth who self-identified as NHW and any race/ethnicity other than Hispanic,
black or Asian/Pacific Islander, were categorized as NHW (n=9).
Height and weight were used to calculate BMI (kg/m2). Age- and sex-specific BMI z-scores
were derived from the Centers for Disease Control and Prevention national standards, and
used to define BMI categories: “underweight or normal weight” if < 85th percentile,
“overweight” if between 85th and 95th percentiles, and “obese” if > 95th percentile (17).
DKA at onset was determined by one of the following: (1) blood bicarbonate < 15 mmol/l or
pH < 7.25 (venous) or <7.30 (arterial or capillary); (2) ICD-9 code 250.1 at discharge; and
(3) diagnosis of DKA in the medical record (18).
Blood samples were analyzed for GADA and IA-2A autoantibodies using a standardized
protocol and common serum calibrator developed by the NIDDK-sponsored standardization
group (19). The cutoff values for positivity were 33 NIDDKU/ml for GADA and 5
NIDDKU/ml for IA-2A. The calculated specificity and sensitivity were 97% and 76%,
respectively, for GADA and 99% and 64%, respectively, for IA-2A (19). FCP was measured
by a two-site immunoenzymetric assay (TOSOH Bioscience, Inc., San Francisco, CA) with
sensitivity of 0.05 ng/ml, and inter-assay coefficient of variation in quality control samples
of 3.8%, 1.6% and 1.8% for low, medium and high levels of FCP, respectively. Hemoglobin
A1C (A1c) was measured by a dedicated ion exchange high performance liquid
chromatography instrument (TOSOH, Bioscience, Inc., San Francisco, CA). All assays were
performed at Northwest Lipid Metabolism and Diabetes Research Laboratories, University
of Washington, which serves as the central laboratory for the Search Study.
Molecular Analysis
HLA class II genotyping was performed with a PCR-based sequence-specific
oligonucleotide probe system. Oligonucleotide probes corresponding to known polymorphic
sequence motifs in HLA DRB1 and DQB1 loci were immobilized on nylon membranes. The
polymorphic second exons of DQB1 and DRB1 were amplified using labeled primers
(biotinylated), denatured, and hybridized to the immobilized probe array. Preliminary
genotype data were imported into Sequence Compilation and Rearrangement Evaluation
(SCORE) software for final genotype determination (9). DRB1-DQB1 haplotypes were
inferred by visual inspection of individual DRB1 and DQB1 genotypes, based on well-
established patterns of linkage disequilibrium (9).
Statistical Analysis
Youth with newly diagnosed diabetes in 2002–2006 from five centers who were at least 3
years of age and completed a SEARCH visit were considered for inclusion in these analyses.
Among these 3,128 youth, we hierarchically excluded those with a health care provider
diagnosis other than type 1 diabetes (n=461), those who did not test positive for GADA or
IA-2A autoantibodies at the initial study visit (n=836), and those without complete HLA
genotyping (n=127). Given that we aimed to examine clinical characteristics and haplotype
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distributions by race/ethnicity, we further excluded Asian/Pacific Islanders (n=29), Native
Americans (n=5) and other race/ethnicities (n=8) due to small sample size, resulting in a
final cohort of 1,662 youth for these analyses.
We present arithmetic means for normally distributed continuous demographic and clinical
characteristics and geometric means for those that were log-transformed. ANOVA was used
to determine significant differences in mean continuous characteristics among the three
racial/ethnic groups. Chi-square was used to assess differences in proportions of categorical
traits. DRB1-DQB1 haplotype frequencies, which are based on the occurrence of a given
haplotype out of the total number of haplotypes (2N), were computed for all observed
haplotypes in the SEARCH sample, by race/ethnicity. Haplotypes with frequencies > 1% in
at least one racial/ethnic group are presented in Table 2. Chi-square was used to determine
significant differences in haplotype frequencies among the groups. Frequencies for all
observed haplotypes are listed in Supplemental Table 1. We categorized haplotypes as
“susceptibility”, “neutral” and “protective” with respect to risk for type 1 diabetes (8) and
for the purposes of this analysis, combined haplotypes according to these risk categories.
Susceptibility haplotypes were defined as DRB1*03-DQB1*XX, DRB1*04-DQB1*0302
and DRB1*0901-DQB1*02; neutral haplotypes as DRB1*01-DQB1*XX; protective
haplotypes as DRB1*04-DQB1*0301, DRB1*0701-DQB1*XX and DRB1*13-DQB1*XX.
We examined associations between haplotypes (presence/absence) and clinical
characteristics by race/ethnicity. Odds ratios and 95% CI for association with categorical
traits were computed with multivariable logistic regression. Multivariable linear regression
was used to determine haplotype associations with continuous traits, with nominal p-values
(p<0.05) reported. Multivariable models for traits assessed at onset were adjusted for sex
and age at diagnosis (where appropriate); traits measured at the study visit were adjusted for
age at diagnosis, sex and duration of diabetes. Statistical analyses were performed using
SAS version 9.2 (SAS Institute).
RESULTS
The study sample consisted of 1,662 youth with autoimmune diabetes (49% female),
ranging in age from 3 to 21 years, of whom 77% were NHW, 10% NHB and 13% Hispanic
(Table 1). The majority of NHW youth (99.3%) reported NHW as their only race/ethnicity.
Among NHB youth, 83.7% self-identified as black or African American only, 15.7% as both
black and NHW, and 0.6% as both black and Asian/Pacific Islander. Most Hispanic youth
self-identified as Mexican or Mexican American (71.1%); others reported Puerto Rican
(4.7%), Cuban (1.0%), Central American (3.8%), South American (3.0%), European
Spanish (5.7%), or “Latino” or “Hispanic” only (10.7%).
Although mean age at diagnosis and mean age at study visit were similar among all racial/
ethnic groups, NHB and Hispanic youth had a slightly longer duration of diabetes at the time
of the visit. NHB youth were also more likely to test positive for GADA than either NHW or
Hispanic youth. NHW and Hispanics were more likely to test positive for IA-2A, and among
all youth who tested positive for IA-2A, had significantly higher mean IA-2A titers than
NHB. NHB and Hispanic youth were more likely to present with DKA at diabetes onset
than NHW youth. Although both NHB and Hispanics had a higher prevalence of overweight
and obesity than NHW, they had similar FCP levels at the study visit.
Overall, 85% of youth in the study were carriers of at least one DRB1*03, DRB1*04 or
DRB1*09 haplotype for susceptibility to type 1 diabetes. However, the distribution of many
specific DRB1-DQB1 haplotypes varied by race/ethnicity (Table 2). While the DRB1*0301-
DQB1*0201 susceptibility haplotype did not differ in frequency among the racial/ethnic
groups, the frequency of the DRB1*0401-DQB1*0302 susceptibility haplotype was
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substantially higher in NHW than NHB or Hispanic youth. DRB1*0405-DQB1*0302 was
more frequent in NHB and Hispanic than NHW youth, while DRB1*0407-DQB1*0302 was
more frequent in Hispanic youth only. The frequencies of susceptibility DRB1*0901-
DQB1*0201 and DRB1*0901-DQB1*0202 haplotypes were significantly higher in NHB
than NHW and Hispanic youth. In general, frequencies of the neutral haplotypes either did
not differ among racial/ethnic groups, or were higher in NHW compared to NHB and
Hispanic youth (e.g. DRB1*0101-DQB1*0501). As expected, haplotypes shown to be
protective for type 1 diabetes were of low frequency among all groups. In fact, the most
protective haplotypes including DRB1*11, DRB1*14, DRB1*15 and DRB1*16 alleles
typically had frequencies ≤ 1% in all racial/ethnic groups (Supplementary Table 1). The
protective haplotype DRB1*0401-DQB1*0301 was more frequent in NHW, while
frequency of modestly protective DRB1*0701-DQB1*0202 was higher among NHB.
While the frequency of susceptibility haplotypes DRB1*03-DQB1*XX were similar among
all racial/ethnic groups, associations with characteristics of diabetes onset were not observed
across all race/ethnicities. DRB1*03-DQB1*XX haplotypes were significantly associated
with positive titers for both GADA and IA-2A in Hispanic youth only (Table 3); Hispanic
youth carrying haplotypes with a DRB1*03 allele had 82% greater odds of testing positive
for both GADA and IA-2A than non-carriers (OR: 1.82, 95% CI: 1.05–3.15). NHW youth
carrying haplotypes with this allele had significantly younger mean age of diabetes onset
compared to non-carriers (9.9 ± 0.2 vs. 10.5 ± 0.2 years; p=0.011) (Supplemental Figure 1).
The susceptibility haplotype DRB1*04-DQB1*0302 was also significantly associated with
positive titers for multiple autoantibodies in Hispanic youth; carriers of this haplotype were
more than twice as likely to test positive for both GADA and IA-2A as non-carriers (OR:
2.13, 95% CI: 1.15–3.94) (Table 3). Hispanic carriers of this haplotype were also more than
twice as likely to have had DKA at onset (OR: 2.38, 95% CI: 1.07–5.31) (Table 3) and
significantly lower mean FCP at the study visit (0.45 ± 0.03 vs. 0.67 ± 0.08 ng/ml, p=0.007)
compared to non-carriers (Supplemental Figure 2).
While neutral haplotypes did not appear to significantly alter risk for multiple autoantibody
positivity, they appeared to have race/ethnicity-specific effects on other characteristics of
diabetes onset. NHB youth with haplotypes containing a DRB1*01 allele were more than
three times as likely to have had DKA at onset (OR= 3.62, 95% CI: 1.18–11.06) (Table 3),
while NHW youth carrying this allele had significantly older age of onset (10.7 ± 0.2 vs.
10.1 ± 0.2 years; p=0.037) compared to non-carriers (Supplemental Figure 1). Interestingly,
the modestly protective haplotypes, DRB1*04-DQB1*0301 and DRB1*0701-DQB1*XX
were associated with increased odds of positive titers for multiple autoantibodies in NHW
(OR= 1.98, 95% CI: 1.32–2.97 and OR=1.51, 95% CI: 1.05–2.17, respectively) (Table 3).
DRB1*04-DQB1*0301 was also associated with older age of onset in NHW youth (11.0 ±
0.3 vs. 10.1 ± 0.1 years; p=0.017) (Supplemental Figure 1). Protective and neutral
haplotypes containing the DRB1*13 allele were generally more frequent in NHB and NHW
youth, and appeared to have a protective effect for multiple autoantibody positivity and
DKA at onset. NHB youth carrying a DRB1*13 allele were 57% less likely to test positive
for both GADA and IA-2A compared to non-carriers (OR= 0.43, 95% CI: 0.19–0.95).
DRB1*13 may also confer protection from DKA at onset in NHB youth (OR= 0.40, 95%
CI: 0.13–1.19) (Table 3).
DISCUSSION
In this diverse sample of 1,662 youth with diabetes, we found the distribution of HLA
DRB1-DQB1 haplotypes to vary by race/ethnicity. DRB1-DQB1 associations with
characteristics of diabetes onset and severity also varied by race/ethnicity, although not
always in accordance with race/ethnicity-specific haplotype frequencies. Moreover, a few
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haplotypes previously shown to be “neutral” or “protective” with respect to risk for type 1
diabetes were associated with diabetes-related characteristics in some groups. As such, these
findings may explain some of the variation in clinical presentation of autoimmune diabetes
by race/ethnicity.
Of the susceptibility haplotypes, the combined frequency of those containing at least one
DRB1*03 allele ranged from 27.5% in Hispanic youth, to 28.8% and 28.9% in NHW and
NHB youth, respectively. The frequency of susceptibility haplotypes DRB1*03-
DQB1*0201 and DRB1*04-DQB1*0302 (28.4% and 34.5%, respectively) in our NHW
sample were slightly lower than those reported by the Type 1 Diabetes Genetics Consortium
(T1DGC) (34.1% and 39.4%, respectively) and other Caucasian samples (6,9,20).
Additionally, the frequency of neutral DRB1*01-DQB1*XX and protective DRB1*04-
DQB1*0301, DRB1*0701-DQB1*XX and DRB1*13-DQB1*XX haplotypes (8.9%, 4.8%,
5.5%, and 6.6%, respectively) were slightly higher than those previously reported in the
T1DGC (7.5%, 1.7%, 3.6%, and 3.1%, respectively) (9). This variation may be due to
differences in the geographic location of proband ascertainment, and/or enrichment of
family members with type 1 diabetes in the T1DGC. Scant data exist on the frequency of
these haplotypes in Hispanic or black individuals with diabetes for comparison, although
others have noted higher frequencies of DQB1*0302 among NHW and Hispanic youth and
DQB1*02XX among black youth with type 1 diabetes, which are consistent with our
findings (12).
Few studies have examined associations between DRB1-DQB1 haplotypes and clinical
characteristics of diabetes onset or severity, especially in black or Hispanic populations.
While the frequency of haplotypes containing a DRB1*03 allele was similar among all
racial/ethnic groups, we found the presence of these haplotypes to be significantly associated
with multiple autoantibody positivity among Hispanic youth only. DRB1*04-DQB1*0302
haplotypes, which were more frequent in NHW and Hispanics, were associated with
multiple autoantibody positivity in both groups. DRB1*04-DQB1*0302 was also
significantly associated with increased risk for DKA in Hispanic youth, which may indicate
a role for this particular set of haplotypes in severity of onset in Hispanics. Interestingly,
despite their “protective” designations, we also found DRB1*04-DQB1*0301 and
DRB1*0701-DQB1*XX to be associated with multiple autoantibody positivity in NHW
youth. This finding is supported by a study conducted in northern European children and
adolescents with type 1 diabetes, which reported both DRB1*04 and DRB1*07 associations
with IA-2A positivity (21). Moreover, Noble et al. recently reported that the effect of
DRB1*0701-DQB1*0201, which was the highest frequency DRB1*07 haplotype in our
sample, particularly among NHB youth, varies by DQA1 allele (22). The presence of
European-derived DQA1*0201 on the haplotype confers protection, while the presence of
DQA1*0301, linked to African ancestry, confers susceptibility to type 1 diabetes (22).
Although DQA1 was not typed in our sample, it is possible that the association observed
with increased autoantibody positivity is due to a greater presence of DQA1*0301 than
DQA1*0201.
We acknowledge the limitations of our investigation. GADA and IA-2A were the only
autoantibodies measured from blood samples drawn at the SEARCH study visit. Therefore,
in restricting our analyses to youth who tested positive for at least one of the two
autoantibodies measured, we excluded those who may have been positive for other diabetes-
related autoantibodies in the absence of GADA or IA-2A. Self-reported race/ethnicity
precluded us from accounting for racial/ethnic admixture in the estimation of haplotype
frequencies and their effects on diabetes-related characteristics. Moreover, the modest
sample sizes for NHB and Hispanic youth precluded us from examining DRB1-DQB1
haplogenotypes in more detail, and limited our power to detect association with some traits;
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most associations observed at a nominal significance level (p<0.05) would not survive
correction for multiple testing. Despite these limitations, our population-based approach
combined with the multi-ethnic composition of this cohort allowed for exploration of HLA-
associated phenotypes in major racial/ethnic groups largely understudied. SEARCH
participants are also well characterized in terms of traits associated with diabetes onset.
In conclusion, the frequencies of DRB1-DQB1 haplotypes and their association with clinical
features of autoimmune diabetes vary across major racial/ethnic groups in the United States.
Our findings also suggest a role for “neutral” and “protective” haplotypes in the severity of
diabetes onset that has not been previously explored, particularly in racial/ethnic minority
groups. Taken together, these findings may explain, in part, the variation in clinical
presentation of autoimmune diabetes within and across racial/ethnic groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
SEARCH Participant Characteristics
Non-Hispanic White (n=1,285) Non-Hispanic Black (n=166) Hispanic (n=211) p-value*
Mean Age at Diagnosis ± SE [yrs] 10.2 ± 0.1 9.8 ± 0.3 10.1 ± 0.3 0.51
Mean Age at Initial Visit ± SE [yrs] 11.4 ± 0.1 11.1 ± 0.3 11.4 ± 0.3 0.76
Mean Diabetes Duration ± SE [months] 9.8 ± 0.2 § 11.0 ± 0.5 11.3 ± 0.4 † 0.001
Sex (%) 0.014
 Female 612 (47.6) 99 (59.6) 103 (48.8)
 Male 673 (52.4) 67 (40.4) 108 (51.2)
Weight Status (%) < 0.001
 Underweight 68 (5.3) 6 (3.7) 14 (6.8)
 Normal Weight 811 (63.6) 81 (49.4) 98 (47.3)
 Overweight 242 (19.0) 33 (20.1) 58 (28.0)
 Obese 155 (12.1) 44 (26.8) 37 (17.9)
Mean BMI z-score ± SE 0.53 ± 0.03 ‡ 0.93 ± 0.08 † 0.70 ± 0.08 < 0.001
Mean A1c % ± SE 7.6 ± 0.04 ‡ 8.6 ± 0.18 †,§ 7.9 ± 0.12 ‡ < 0.001
Type of Autoantibody Present (%)
 GADA 870 (67.7) 131 (78.9) 149 (70.6) 0.011
 IA-2A 1067 (83.0) 122 (73.5) 174 (82.5) 0.010
Number of Autoantibodies (%) 0.77
 GADA or IA-2A only 633 (49.3) 79 (47.6) 99 (46.9)
 Both GADA and IA-2A 652 (50.7) 87 (52.4) 112 (53.1)
Mean Titers GADA ± SE || 239.6 ± 9.2 293.2 ± 28.8 240.7 ± 22.7 0.16
Mean Titers IA-2A ± SE || 214.9 ± 7.2 ‡ 125.2 ± 15.2 †,§ 182.1 ± 15.8 † < 0.001
Mean Fasting C-peptide ± SE [ng/mL] || 0.49 ± 0.01 0.50 ± 0.04 0.51 ± 0.04 0.92
DKA at onset ¶ (%) 0.031
 No 709 (72.9) 81 (63.8) 104 (65.8)
 Yes 264 (27.1) 46 (36.2) 54 (34.2)
*
P-values derived from ANOVA for continuous traits or chi-square for categorical traits
†
significantly different than Non-Hispanic White (p < 0.05)
‡
significantly different than Non-Hispanic Black (p < 0.05)
§
significantly different than Hispanic (p < 0.05)
||
Values shown are geometric means with SE calculated using the Delta Method
¶
DKA at onset available for 1,258 youth.
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